Literature DB >> 10871826

Lesion pattern in patients with multiple sclerosis and depression.

D Berg1, T Supprian, J Thomae, M Warmuth-Metz, A Horowski, B Zeiler, T Magnus, P Rieckmann, G Becker.   

Abstract

To assess if a specific lesion pattern or changes of the basal limbic system as seen in primary depression and depression associated with neurodegenerative disorders might be identified in depressive multiple sclerosis (MS) patients, we submitted 78 MS patients to a MRI examination consisting of a quantitative measurement of lesions and of hyperintense signals from the pontomesencephalic midline (raphe). Furthermore relaxometry of the pontomesencephalic midline, a transcranial ultrasound examination rating its echogenicity semiquantitatively and a standardized neurological, neuropsychiatric and neuropsychological assessment were obtained. Thirty-one patients fulfilled the DSM-IV criteria for depression. Depressed MS patients had a significantly larger temporal lesion load than non-depressed MS patients, especially on the right side. A trend of difference was detected for lesions of the right parietal lobe, the right frontal lobe, the cerebellum and the total lesion load. Neither hyperintense signals or relaxometry nor echogenicity of the region at the level of the pontomesencephalic midline were significantly different between the groups. We conclude that depression in MS patients is not associated with an alteration of the basal limbic system at the brainstem as seen in Parkinson's disease or unipolar depression but with an increased lesion load of the projection areas of the basal limbic system.

Entities:  

Mesh:

Year:  2000        PMID: 10871826     DOI: 10.1177/135245850000600304

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  25 in total

Review 1.  White matter hyperintensities: from medical comorbidities to bipolar disorders and back.

Authors:  Eva Gunde; Ryan Blagdon; Tomas Hajek
Journal:  Ann Med       Date:  2011-07-13       Impact factor: 4.709

Review 2.  Imaging and depression in multiple sclerosis: a historical perspective.

Authors:  Fabio Giuseppe Masuccio; Giulia Gamberini; Massimiliano Calabrese; Claudio Solaro
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

Review 3.  The neuropsychology of multiple sclerosis: contributions of neuroimaging research.

Authors:  H A Wishart; L Flashman; A J Saykin
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 4.  Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis.

Authors:  Richard M Sobel; Susan Lotkowski; Steven Mandel
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 5.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

6.  Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life.

Authors:  Mariam Hanna; Lauren Beth Strober
Journal:  Mult Scler Relat Disord       Date:  2020-06-06       Impact factor: 4.339

7.  Neuropsychological deficits but not coping strategies are related to physical disability in multiple sclerosis.

Authors:  Claus G Haase; Marc Lienemann; Pedro M Faustmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

Review 8.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

9.  Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis.

Authors:  Sebastian Horowski; Uwe K Zettl; Reiner Benecke; Uwe Walter
Journal:  J Neurol       Date:  2010-08-26       Impact factor: 4.849

Review 10.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.